Telesis Bio, Inc. (OTCMKTS:TBIO) Stock Short Interest Report for October

Telesis Bio, Inc. (OTCMKTS:TBIO) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 81 shares, a decline of 54.0% from the September 30th total of 176 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 485 shares, the days-to-cover ratio is presently 0.2 days.

Telesis Bio Stock Down 74.1%

Shares of TBIO opened at $0.01 on Friday. The company has a market cap of $18,000.00, a PE ratio of -0.00 and a beta of 2.58. The business has a fifty day moving average of $0.01 and a 200 day moving average of $0.03. Telesis Bio has a 52-week low of $0.00 and a 52-week high of $0.15.

Telesis Bio Company Profile

Telesis Bio, Inc develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps.

The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology.

Telesis Bio was formerly known as Codex DNA and changed its corporate name in 2023.